RachidCBazMD

Hematologic Oncology

Physician

Overview of Dr. Baz

Dr. Rachid Baz is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute, and H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 17 years. Dr. Baz accepts several types of health insurance, listed below. He is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He also speaks multiple languages, including Arabic and French. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(253) 252-1223

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007
Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
American University of Beirut Faculty of MedicineClass of 2000

Certifications & Licensure

FL State Medical License 2008 - 2026
OH State Medical License 2001 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Start of enrollment: 2004 Nov 01
Completed
Phase 2
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) Start of enrollment: 2008 Jan 01
Completed
Phase 2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma Start of enrollment: 2010 Jan 14
Completed
Phase 2
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Sep 23
Completed
Phase 1, Phase 2
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
COMPLETED
PHASE1, PHASE2
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma Start of enrollment: 2019 Nov 22
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao
Cancer Research. 2025-01-15
Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.
Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan
Blood. 2025-01-06
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes.
Ciara L Freeman, Jerald Noble, Meghan Menges, Ricardo Villanueva, Justyn Y Nakashima
Blood. 2024-12-09

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Corre...
Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Novel Antibody Strategies in Relapsed/Refractory Myeloma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Year in Review: Multiple MyelomaDecember 2nd, 2024
$Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval$
Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019
Plethora of Novel Agents Transforming Outcomes in Multiple MyelomaJuly 28th, 2017
Join now to see all

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Medical Association - AMA
Member

Other Languages

Arabic, French

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Coventry Florida - Employer Group PPO
First Health PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment